Volumetric changes in hypothalamic subunits in patients with relapsing remitting multiple sclerosis

被引:4
|
作者
Genc, Baris [1 ]
Sen, Sedat [2 ]
Aslan, Kerim [2 ,3 ]
Incesu, Luetfi [3 ]
机构
[1] Samsun Educ & Res Hosp, Dept Radiol, TR-55060 Samsun, Turkiye
[2] Ondokuz Mayis Univ, Dept Neurol, Sch Med, Samsun, Turkiye
[3] Ondokuz Mayis Univ, Dept Radiol, Sch Med, Samsun, Turkiye
关键词
Relapsing remitting multiple sclerosis; Hypothalamus; Freesurfer; Brain atrophy; ADRENAL AXIS ACTIVITY; COGNITIVE FATIGUE; LESIONS;
D O I
10.1007/s00234-023-03122-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Studies on hypothalamic changes in patients with relapsing remitting multiple sclerosis (RRMS) are very scarce, despite the fact that the relationship with the hypothalamus is frequently reported. The aim of the study was to determine the volume of the hypothalamic subunits and the total hypothalamus and its relationship with the total demyelinating lesion volume (TLV) and expanded disability status scale (EDSS) in RRMS patients. Methods In this cross-sectional study, anterior-superior, superior tubular, posterior hypothalamus, anterior-inferior, inferior tubular subunits of hypothalamus, and total hypothalamus volume were calculated, with fully automatic analysis methods using volumetric T1 images of 65 relapsed RRMS patients and 68 healthy controls (HC). Volume changes in the hypothalamus and its subunits in RRMS patients were examined using multivariate analysis of covariance (MANCOVA). The relationship of these volumes with EDSS and TLV was investigated by partial correlation analysis. Results There is volume reduction in total hypothalamus (F = 13.87, p < 0.001), anterior-superior (F = 19.2, p < 0.001), superior tubular (F = 10.1, p = 0.002) subunits, and posterior hypothalamus (F = 19.2, p < 0.001) volume in RRMS patients. EDSS correlates negatively with anterior-superior (p = 0.017, r = - 0.333), superior tubular subunits (p = 0.023, r = - 0.439), posterior hypothalamus (p < 0.001, r = - 0.511), and whole hypothalamus volume (p = 0.001, r = - 0.439). TLV correlates negatively with anterior superior (p < 0.001, r = - 0.565), anterior inferior (p = 0.002, r = - 0.431), superior tubular subunits (p = 0.002, r = - 0.432), posterior hypothalamus (p < 0.001, r = - 0.703), and whole hypothalamus (p < 0.001, r = - 0.627) volumes. Conclusion This study demonstrates a reduction in total hypothalamus volume, anterior-superior, superior tubular, and posterior hypothalamus in patients with RRMS. Anterior-superior and superior tubular subunit, posterior hypothalamus, and total hypothalamus volume were negatively correlated with TLV and EDSS scores.
引用
收藏
页码:899 / 905
页数:7
相关论文
共 50 条
  • [31] Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background
    Rito, Yamel
    Flores, Jesus
    Fernandez-Aguilar, Angeles
    Escalante-Membrillo, Carmen
    Barboza, Miguel A.
    Amezcua, Lilyana
    Corona, Teresa
    ACTA NEUROLOGICA BELGICA, 2018, 118 (01) : 47 - 52
  • [32] Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing-Remitting Multiple Sclerosis
    Escribano, Begona M.
    Aguilar-Luque, Macarena
    Bahamonde, Carmen
    Conde, Cristina
    Lillo, Rafael
    Sanchez-Lopez, Fernando
    Giraldo, Ana I.
    Cruz, Antonio H.
    Luque, Evelio
    Gascon, Felix
    Aguera, Eduardo
    Tunez, Isaac
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (31) : 4876 - 4880
  • [33] Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients
    Vogt, MHJ
    Floris, S
    Killestein, J
    Knol, DL
    Smits, M
    Barkhof, F
    Polman, CH
    Nagelkerken, L
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 155 (1-2) : 155 - 160
  • [34] CONTEMPORARY TREATMENT OPTIONS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Salhofer-Polanyi, S.
    Leutmezer, F.
    DRUGS OF TODAY, 2014, 50 (05) : 365 - 383
  • [35] Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
    Shima, Ayano
    Hamaguchi, Tsuyoshi
    Tada, Yasutake
    Yamada, Masahito
    INTERNAL MEDICINE, 2020, 59 (01) : 121 - 124
  • [36] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [37] MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-Ia
    Gasperini, C
    Paolillo, A
    Giugni, E
    Galgani, S
    Bagnato, F
    Mainero, C
    Onesti, E
    Bastianello, S
    Pozzilli, C
    MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (02) : 119 - 123
  • [38] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Jens Ingwersen
    Orhan Aktas
    Hans-Peter Hartung
    Neurotherapeutics, 2016, 13 : 47 - 57
  • [39] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Ingwersen, Jens
    Aktas, Orhan
    Hartung, Hans-Peter
    NEUROTHERAPEUTICS, 2016, 13 (01) : 47 - 57
  • [40] Novel Therapeutic Approaches to Multiple Sclerosis: Neuroprotective Drugs for Relapsing-Remitting Multiple Sclerosis
    Pugliese, Marco
    Espinosa-Parrilla, Juan F.
    Bustos, Javier
    Campas, Clara
    de Frias, Merce
    Sorrosal, Georgina
    ADVANCES IN NEUROIMMUNE BIOLOGY, 2013, 4 (03) : 187 - 204